The current testing rate for BRCA 1/2 mutations is currently 68% in HER2-negative early breast cancer, but eligible patients could receive better care if tested. The current rate of BRCA1/2 testing ...
Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — More than one-third of U.S. adults diagnosed with metastatic HER2-negative breast cancer in 2023 ...
Scientists have developed a new clinical pathway for testing for the cancer-causing faults in the BRCA gene that could ensure patients get the right treatment and boost the number of people who get ...
From left: Dr Allan Njau, Consultant Anatomic and Molecular Pathologist, Dr Affrin Shaffi, and Dr Njoki Njiraini during the AstraZeneca BRCA testing launch in Nairobi, November 28, 2025. [Ryan Kerubo, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results